Contemporary Hormonal Management of Advanced Prostate Cancer

ONCOLOGY

Volumn 12, Issue 4, 1998, Pages 499-505

  Moul, Jodd W ^a,b,c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Ctr for Prost Dis Research (CPDR)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN ANTAGONIST;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER HORMONE THERAPY; CANCER STAGING; HUMAN; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0031971186     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
2. Muggins C, Hodges CV: Studies on prostatic cancer I: The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
3. Crawford ED: Changing concepts in the management of advanced prostate cancer. Urology 44:67-74, 1994
4. Epstein BE, Hanks GE: Prostate cancer: Evaluation and radiotherapeutic management. CA Cancer J Clin 42:223-240, 1992.
5. Monne JE: 1992 Staging system for prostate cancer. Semin Urol 11:10-13, 1993.
6. Zeitman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer: Clinical significance and therapeutic implications. Cancer 71:959-962, 1993.
7. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994.
8. Ruckle HC, Klee GG, Oesteding JE: Prostate-specific antigen: Concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc 69:69-79, 1994.
9. Rogers E, Ohori M, Kassabian VS, et al: Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels. J Urol 153:104-110, 1995.
10. Trapasso JG, DeKernion JB, Smith RB, Dorey F The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994.
11. Critz FA, Levinson AK, Williams WH, et al: Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer. J Clin Oncol 14:2889-2892, 1996.
12. Partin AW, Piantodosi S, Sanda MG, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45:831-838, 1995.
13. Bauer JJ, Connelly RR, Sesterhenn IA, et al: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer (abstract). J Urol 157(suppl):298, 1997.
14. Bauer JJ, Sesterhenn IA, Mostofi FK, et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 156:1511-1516, 1996.
15. Cox LE, Crawford ED: Estrogens in the treatment of prostate cancer. J Urol 154:1991-1998, 1995.
16. Santen RJ: Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 75:685-689, 1992.
17. Sharifi R, Soloway M, Leuprolide Study Group: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 143:68-71, 1990.
18. Sharifi R, Hudson P, Stein B: Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 18:647-657, 1996.
19. Cassileth BR, Soloway MS, Vogelzang NJ, et al: Patients' choice of treatment in stage D prostate cancer Urology 33(suppl):57-62, 1989.
20. Labrie F, Dupont A, Belanger A, et al: Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer. A marked improvement in survival. J Steroid Biochem Mol Biol 23:833-841, 1985.
21. Janknegt RA, Abbou CC, Bartoletti R, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77-83, 1993.
22. Beland G, Elhilali M, Fradet Y, et al: Total androgen blockade versus castration in metastatic cancer of the prostate, in Motta M, Seno M (eds): Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects, pp 302-311. Bussum, England, Medicom, 1988.
23. Eisenberger MA, Crawford ED, Wolf M, et al: Prognostic factors in stage D2 prostate cancer, important implications for future trials: Results of a cooperative intergroup study. Semin Oncol 21:613-619, 1994.
24. Caubet J, Tosteson TD, Dong EW, et al: Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized trials using nonsteroidal antiandrogen. Urology 49:71-78, 1997.
25. Crawford ED, Eisenberger MA, McLeod DG, et al: Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: Results of NCI intergroup study 0105 (SWOG and ECOG) (abstract). J Urol 157(suppl):336, 1997.
26. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3,283 deaths in 5,710 patients. Lancet 346:265-269, 1995.
27. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 15:1013, 1997.
28. Pilepich MV, Krall JM , Al-Sanat M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995.
29. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally-advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337:295-300, 1997.
30. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 79:2357246, 1997.
31. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 32:1126, 1973.
32. Kozlowski JM, Ellis WI, Grayhack JT: Advanced prostatic carcinoma: Early vs late endocrine therapy. Urol Clin North Am 18:1 5-24, 1991.
33. Kramolowsky EV: The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 139:1242-1244, 1988.
34. Zincke H: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome Urology 33(suppl):27-35, 1989
35. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444, 1997.
36. Preston DM, Torrens JI, Duncan WE, et al: Evaluation of bone mineral density in men receiving total androgen blockade therapy for prostate cancer: Preliminary results (abstract) J Urol 157(suppl):335, 1997
37. Srivastava S, Katayose D, Tong YA, et al: Rccombinant adenovirus vector expressing wild type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46:843-848, 1995.
38. Adolfsson J: Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol 149:326-329, 1993.
39. Zincke H, Fleming TR, Furlow WL, et al Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer 47:1901-1910, 1981.
40. Andros EA, Daneshari F, Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcilfoma of the prostate Clin Invest Med 16:510-515, 1993.
41. Soloway MS, Hachiya T, Ruiz HE, et al: Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate specific antigen. World J Urol 11:221-226, 1993.
42. Soloway MS, Sharifi R, Wajsman Z, et al Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNXM0) prostate cancer J Urol 154:424-428, 1995.
43. Goldenberg SL, Bruchovsky N, Gleave M, et al: Intermittent androgen suppression in the treatment of prostate cancer: An update (abstract) Urol 157(suppl):333, 1997